Anticancer Agents
Anticancer Agents - Related Videos
04:11
Colony Formation Assay: Assessing the Efficacy of Anticancer Agents on Colony-Forming Lung Cancer Cells
0 Views •
2023
This video describes the colony formation assay, which helps determine lung cancer cells' ability to proliferate indefinitely and form individual colonies. We can analyze the effect of an anticancer agent on the colony-forming cells by analyzing the changes in the number and/or size of the resulting colonies.
08:03
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
0 Views •
Cited by 7 •
2016
Photodynamic therapy (PDT) is an alternative choice for lung cancer treatment. To increase the therapeutic effect of PDT, lung cancer-targeted nanoparticles combined with chemotherapy were developed. Both in vitro and in vivo anticancer efficacies of PDT with prepared nanoparticles were evaluated.
01:49
An Assay To Evaluate the Anticancer Effects of Lactobacillus Cell-Free Supernatant
0 Views •
2025
This video demonstrates an in vitro assay to study the anticancer effects of Lactobacillus cell-free supernatant (LCFS). Upon exposing colorectal cancer spheroids to varying doses of LCFS, the interaction with the bacterial metabolites in LCFS induces apoptosis in the cancer cells, disrupting the spheroid structure and leading to cell death in a dose-dependent manner.
07:20
Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
0 Views •
Cited by 1 •
2014
This protocol describes the use of amide coupling reactions of isonicotinic acid and diaminoalkanes to form bridging ligands suitable for use in the synthesis of multinuclear platinum complexes, which combine aspects of the anticancer drugs BBR3464 and picoplatin.
11:27
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
0 Views •
Cited by 5 •
2016
This protocol describes the preparation and characterization of a dendrimeric magnetic resonance imaging (MRI) contrast agent that carries cyclen-based macrocyclic chelates coordinating paramagnetic gadolinium ions. In a series of MRI experiments in vitro, this agent produced an amplified MRI signal when compared to the commercially available monomeric analogue.
FAQs
Molecular structure helps determine how an anticancer agent behaves in biological and chemical settings. Chemists relate structural features to activity against cancer cells, solubility, stability, and toxicity. These relationships guide medicinal chemistry decisions, allowing researchers to compare compounds and identify structural changes that may improve performance or reduce undesirable effects during development.
Selectivity influences the balance between therapeutic benefit and toxicity. An agent may be more useful when its effects reflect differences between tumor cells and normal cells, rather than affecting both populations equally. Studying these differences helps chemists and researchers evaluate whether a compound can restrict uncontrolled growth while producing fewer harmful effects in healthy tissue.
Different agents interfere with distinct processes required for cancer-cell survival and proliferation. Some inhibit DNA synthesis, others block cell-cycle progression, disrupt microtubules, or interfere with signaling pathways that support uncontrolled growth. Comparing these mechanisms helps explain why compounds can produce different biological effects and provides a basis for selecting complementary treatment strategies.
Drug resistance is an important consideration when evaluating anticancer agents because cancer cells may become less responsive to treatment. Chemistry research addresses this challenge by relating molecular structure to activity and by investigating combinations of agents with different mechanisms. Such approaches can support treatment designs that target more than one growth-related process and potentially improve therapeutic outcomes.
Chemistry-focused development connects the design, synthesis, and evaluation of candidate compounds. Researchers first use structure-activity relationships to guide molecular design, then prepare compounds and assess properties such as activity, solubility, stability, and toxicity. This integrated workflow helps identify candidates whose chemical characteristics and biological performance are suitable for further investigation.
These properties provide complementary information about a candidate’s suitability. Activity indicates whether the compound produces the intended biological effect, while solubility and stability describe important chemical behavior. Toxicity helps reveal undesirable effects. Considering all of these characteristics together prevents evaluation from focusing on activity alone and supports more informed medicinal chemistry decisions.
These approaches represent different ways of applying anticancer agents in treatment research. Chemotherapy uses agents selected for their ability to affect cancer-cell processes, targeted therapies focus on particular growth-supporting pathways, and combination treatments bring agents with distinct actions together. Chemistry supports all three areas by guiding compound design and evaluating how molecular properties relate to therapeutic outcomes.